

Ref. No: 1841
Date: 19/06/25
Subject: Melanoma

REQUEST

Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- Cobimetinib
- Dabrafenib
- Dabrafenib + Trametinib
- Dacarbazine
- Denosumab
- Encorafenib + Binimetinib
- Ipilimumab monotherapy
- Ipilimumab + Nivolumab
- Nivolumab monotherapy
- Nivolumab + Relatlimab
- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib + Cobimetinib
- Other active systemic anti-cancer therapy
- Palliative care only

This is managed by Clatterbridge so will be zero for this Trust

Q2. Does your trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.

Yes:

Memlart-II pateints:120	opened 08/09/2021	number of
EORTC 1208 – minitub patients:77	opened 03/11/2016	number of

Please note: the above trials do not involve any SACT. CCC will need to be contacted for trials involving SACT for melanoma.